BioVaxys
Updated: February 25, 2026
Founders: Kenneth Kovan, David Berd
Country: USA | Funding: $15.2M (+)
Founded: 2018
Website: https://biovaxys.com/
BioVaxys develops immunotherapeutic cancer vaccines targeting lymphoma and ovarian cancer. The company develops them using its proprietary DPX delivery platform. Unlike conventional emulsions or lipid nanoparticles that release their contents systemically, DPX is fully synthetic and compatible with peptides, proteins, mRNA, virus-like particles and small molecules. It is ideal for mRNA delivery, remaining localized at the injection site with superior stability compared to LDL. Maveropepimute-S, the company's lead clinical drug based on this platform, demonstrated an overall response rate of 21% and a disease control rate of 63% in recurrent ovarian cancer. In relapsed/refractory DLBL, the combination of MVP-S and Keytruda achieved complete remission in 3 of 6 evaluable patients. This means that no detectable cancer cells remained after treatment.
Founded: 2018
Website: https://biovaxys.com/
BioVaxys develops immunotherapeutic cancer vaccines targeting lymphoma and ovarian cancer. The company develops them using its proprietary DPX delivery platform. Unlike conventional emulsions or lipid nanoparticles that release their contents systemically, DPX is fully synthetic and compatible with peptides, proteins, mRNA, virus-like particles and small molecules. It is ideal for mRNA delivery, remaining localized at the injection site with superior stability compared to LDL. Maveropepimute-S, the company's lead clinical drug based on this platform, demonstrated an overall response rate of 21% and a disease control rate of 63% in recurrent ovarian cancer. In relapsed/refractory DLBL, the combination of MVP-S and Keytruda achieved complete remission in 3 of 6 evaluable patients. This means that no detectable cancer cells remained after treatment.
